- Home
- ATHA vs DFLI Comparison
ATHA vs DFLI Comparison
Compare ATHA & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- DFLI
- Stock Information
- Founded
- ATHA 2011
- DFLI 2020
- Country
- ATHA United States
- DFLI United States
- Employees
- ATHA N/A
- DFLI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- DFLI Electronic Components
- Sector
- ATHA Health Care
- DFLI Technology
- Exchange
- ATHA Nasdaq
- DFLI Nasdaq
- Market Cap
- ATHA 14.8M
- DFLI 14.5M
- IPO Year
- ATHA 2020
- DFLI N/A
- Fundamental
- Price
- ATHA $0.36
- DFLI $0.27
- Analyst Decision
- ATHA Hold
- DFLI Strong Buy
- Analyst Count
- ATHA 3
- DFLI 1
- Target Price
- ATHA $0.50
- DFLI $1.50
- AVG Volume (30 Days)
- ATHA 159.8K
- DFLI 21.5M
- Earning Date
- ATHA 11-06-2025
- DFLI 11-13-2025
- Dividend Yield
- ATHA N/A
- DFLI N/A
- EPS Growth
- ATHA N/A
- DFLI N/A
- EPS
- ATHA N/A
- DFLI N/A
- Revenue
- ATHA N/A
- DFLI $54,536,000.00
- Revenue This Year
- ATHA N/A
- DFLI $28.01
- Revenue Next Year
- ATHA N/A
- DFLI $43.54
- P/E Ratio
- ATHA N/A
- DFLI N/A
- Revenue Growth
- ATHA N/A
- DFLI 4.80
- 52 Week Low
- ATHA $0.22
- DFLI $0.15
- 52 Week High
- ATHA $0.83
- DFLI $5.78
- Technical
- Relative Strength Index (RSI)
- ATHA 36.59
- DFLI 46.88
- Support Level
- ATHA $0.35
- DFLI $0.26
- Resistance Level
- ATHA $0.40
- DFLI $0.31
- Average True Range (ATR)
- ATHA 0.02
- DFLI 0.03
- MACD
- ATHA -0.00
- DFLI -0.00
- Stochastic Oscillator
- ATHA 11.86
- DFLI 15.22
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.